Koninklijke DSM (RDSMY) Stock Rating Lowered by ValuEngine
Koninklijke DSM (OTCMKTS:RDSMY) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Friday.
A number of other equities research analysts have also recently weighed in on the company. Deutsche Bank raised Koninklijke DSM from a “hold” rating to a “buy” rating in a report on Friday. Zacks Investment Research cut Koninklijke DSM from a “buy” rating to a “sell” rating in a report on Tuesday, November 7th. Finally, began coverage on Koninklijke DSM in a report on Friday, September 1st. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $24.00.
Koninklijke DSM (OTCMKTS RDSMY) traded up $0.06 on Friday, hitting $23.47. The stock had a trading volume of 84,746 shares, compared to its average volume of 38,687. The company has a market capitalization of $16,980.00, a PE ratio of 29.26, a PEG ratio of 2.89 and a beta of 1.28. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.11 and a current ratio of 1.74. Koninklijke DSM has a 52 week low of $14.50 and a 52 week high of $23.50.
Koninklijke DSM Company Profile
Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company’s segments include Nutrition, Performance Materials, Innovation Center and Corporate Activities. Its Nutrition segment includes DSM Nutritional Products and DSM Food Specialties.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Koninklijke DSM NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM NV and related companies with MarketBeat.com's FREE daily email newsletter.